Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2011 3
2012 3
2013 2
2014 6
2015 6
2016 1
2017 1
2019 2
2022 7
2023 3
2024 2
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Preventing HIV in young women in Africa.
Gengiah TN, Abdool Karim Q. Gengiah TN, et al. Lancet HIV. 2025 Feb;12(2):e83-e84. doi: 10.1016/S2352-3018(24)00309-6. Epub 2024 Dec 13. Lancet HIV. 2025. PMID: 39681127 No abstract available.
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention.
Karim QA, Archary D, Barré-Sinoussi F, Broliden K, Cabrera C, Chiodi F, Fidler SJ, Gengiah TN, Herrera C, Kharsany ABM, Liebenberg LJP, Mahomed S, Menu E, Moog C, Scarlatti G, Seddiki N, Sivro A, Cavarelli M. Karim QA, et al. Among authors: gengiah tn. Front Immunol. 2022 Dec 6;13:1055042. doi: 10.3389/fimmu.2022.1055042. eCollection 2022. Front Immunol. 2022. PMID: 36561760 Free PMC article. Review.
Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial.
Mahomed S, Garrett N, Potloane D, Sikazwe IT, Capparelli E, Harkoo I, Gengiah TN, Zuma NY, Osman F, Mansoor L, Archary D, Myeni N, Radebe P, Samsunder N, Doria-Rose N, Carlton K, Gama L, Koup RA, Narpala S, Serebryannyy L, Moore P, Williamson C, Pozzetto B, Hankins C, Morris L, Karim QA, Abdool Karim S. Mahomed S, et al. Among authors: gengiah tn. BMJ Open. 2023 Aug 28;13(8):e076843. doi: 10.1136/bmjopen-2023-076843. BMJ Open. 2023. PMID: 37640457 Free PMC article.
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial.
Mahomed S, Garrett N, Capparelli EV, Osman F, Mkhize NN, Harkoo I, Gengiah TN, Mansoor LE, Baxter C, Archary D, Yende-Zuma N, Samsunder N, Carlton K, Narpala S, McDermott AB, Doria-Rose NA, Moore PL, Morris L, Abdool Karim Q, Mascola JR, Abdool Karim SS. Mahomed S, et al. Among authors: gengiah tn. Lancet HIV. 2023 Apr;10(4):e230-e243. doi: 10.1016/S2352-3018(23)00003-6. Lancet HIV. 2023. PMID: 37001964 Clinical Trial.
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
Abdool Karim SS, Abdool Karim Q, Kharsany AB, Baxter C, Grobler AC, Werner L, Kashuba A, Mansoor LE, Samsunder N, Mindel A, Gengiah TN; CAPRISA 004 Trial Group. Abdool Karim SS, et al. Among authors: gengiah tn. N Engl J Med. 2015 Aug 6;373(6):530-9. doi: 10.1056/NEJMoa1410649. N Engl J Med. 2015. PMID: 26244306 Free PMC article. Clinical Trial.
38 results